Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Northstar Gold Signs MOU with Hunan Nonferrous Ltd. to Develop Gold Resource (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Oncolytics Biotech Inc
T.ONC
Alternate Symbol(s):
ONCY
Healthcare
Biotechnology
Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and...
adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:ONC)
New Post
View:
Posts & Comments
Threaded Posts
Prev
...
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
...
Next
(5620)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Aug 20, 2024 3:06pm
RE:RE:RE: Pelareorep + Paclitaxel = ADC/HER2 failed breast cancer
ONCY will have 13 years of FDA marketing exclusivity from the date of FDA approval for pelareorep in breast cancer for example. And another 13 year of market exclusivity for pancreatic cancer, as
...more
(5620)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Aug 20, 2024 3:01pm
RE:RE: Pelareorep + Paclitaxel = ADC/HER2 failed breast cancer
According to an October 2023 paper in the Oncologist regarding the ' Evolving Landscape of Immune Checkpoint Inhibitors and Antibody-Drug Conjugates in the Treatment of Early Breast Cancer '
...more
Northstar Gold Signs MOU with Hunan Nonferrous Ltd. to Develop Gold Resource
posted Sep 19, 2024 9:00am by
Northstar Gold Corp.
-
|
The MOU grants Hunan Nonferrous the opportunity to explore and develop a near-surface NI43-101 gold mineral resource at Northstar’s 100%-owned Miller Copper-Gold Property, located 18 kilometers southeast of Kirkland Lake, Ontario. This will be achieved by diamond drilling up to 10,000 meters, allowing Hunan Nonferrous to earn a negotiated interest in the resultant NI43-101 gold resource. ...read more
(1395)
•••
Azzak34
X
View Profile
View Bullboard History
Comment by
Azzak34
on Aug 20, 2024 2:58pm
RE:RE:weekend update & week ahead
Haha what a childish little buffoon. Every call yoube made on here is in the dirt. I asked you before you before to share your wisdom. What should we buy, for how much and when do we sell
...more
(96)
•••
Quentin30
X
View Profile
View Bullboard History
Comment by
Quentin30
on Aug 20, 2024 2:47pm
RE:weekend update & week ahead
"Could everything fall flat? Possible. Not likeky." some folk just don't know when to throw in the towel on a company...? even Matt couldn't take lying to investors anymore..
...more
(5620)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Aug 20, 2024 2:34pm
RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE: Pelareorep + Paclitaxel = ADC/HER2 failed breast cancer
Should read : " .... and in a basic way explain how ONCY's pelareorep is also able to remodel the TME and overcome T-cell resistance and T-cell exhaustion."
(5620)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Aug 20, 2024 2:31pm
RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE: Pelareorep + Paclitaxel = ADC/HER2 failed breast cancer
As part of the pro-inflammatory activity, certain signals, referred to as “damage-associated molecular patterns”, (DAMPs) are emitted. DAMPs are endogenous molecules that would have been
...more
(5620)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Aug 20, 2024 12:26pm
RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE: Pelareorep + Paclitaxel = ADC/HER2 failed breast cancer
Berry et.al. (2020) " ...data demonstrate that crosslinking chemotherapeutic agents to oncolytic viruses facilitates functional drug delivery to cells targeted by the virus, making it a
...more
(5620)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Aug 19, 2024 11:49am
RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE: Pelareorep + Paclitaxel = ADC/HER2 failed breast cancer
Daichii Sanyo's Enhertu consists of a HER2 monoclonal antibody (trastuzumab) attached to a topoisomerase I inhibitor (DXd) payload,
(5620)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Aug 19, 2024 10:14am
RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE: Pelareorep + Paclitaxel = ADC/HER2 failed breast cancer
All FDA Approved ADC Therapies Drug
...more
(5620)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Aug 19, 2024 10:11am
RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE: Pelareorep + Paclitaxel = ADC/HER2 failed breast cancer
In a key mechanism of ADCs, once the antibody part of the drug binds to the target antigen expressed on the surface of tumor cells, the drug is absorbed into the tumor, where it releases the toxic
...more
(5620)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Aug 19, 2024 9:58am
RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE: Pelareorep + Paclitaxel = ADC/HER2 failed breast cancer
" Merck’s sac-TMT is an antibody-drug conjugate (ADC) targeting TROP2, a protein that’s overexpressed in many tumors and plays a part in promoting cancer. The first TROP2-directed ADC
...more
(5620)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Aug 19, 2024 9:48am
RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE: Pelareorep + Paclitaxel = ADC/HER2 failed breast cancer
Additionally Stewart et.al. (2019) found that "topoisomerase inhibitors are a class of drugs that enhance reovirus infectivity and cytotoxicity of triple-negative breast cancer cells."
...more
(5620)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Aug 18, 2024 9:42pm
RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE: Pelareorep + Paclitaxel = ADC/HER2 failed breast cancer
Should read : ONCY's pelareorep, which enhances topoisomerase I inhibitors, + the chemotherapy paclitaxel can further enhance the efficacy of CPIs, as already demonstrated, thus providing an
...more
(5620)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Aug 18, 2024 9:39pm
RE:RE:RE:RE:RE:RE:RE:RE:RE:RE: Pelareorep + Paclitaxel = ADC/HER2 failed breast cancer
ONCY's pelareorep, which enhances including topoisomerase I inhibitors, + the chemotherapy paclitaxel can enhance the efficacy of CPIs providing an opportunity to combine immune CPI therapy
...more
Prev
...
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Mining Player Sells Off Promising Project for Millions – Here's Where the Cash is Headed
EnviroGold Global Announces Appointment of Chief Operating Officer